Entyvio® (vedolizumab) Approved in Japan for the Treatment of Patients with Moderately to Severely Active Crohn`s Disease
(WorldNews Japan)

- New treatment option for adult patients with moderately to severely active Crohn`s disease in Japan Osaka, Japan, May 22, 2019 --- Takeda Pharmaceutical Company Limited (`Takeda`) (TSE: 4502/NYSE: TAK) today announced that it has obtained approval from the Ministry of Health, Labour and Welfare (MHLW) for an additional indication for Entyvio® (generic name: vedolizumab, development code: MLN0002) for the treatment of adult patients with moderately to severely active Crohn`s disease (CD) in Japan. Entyvio was also approved in Japan in July 2018 for the treatment of adult patients with moderately to severely active ulcerative colitis with the medicine launched in November 2018. The...